Literature DB >> 26238376

The prognostic value of hepatic venous pressure gradient in patients with cirrhosis is highly dependent on the accuracy of the technique.

Gilberto Silva-Junior1, Anna Baiges1, Fanny Turon1, Ferran Torres2,3, Virginia Hernández-Gea1,4, Jaime Bosch1,4, Juan Carlos García-Pagán1,4.   

Abstract

UNLABELLED: Hepatic venous pressure gradient (HVPG), the difference between wedged (WHVP) and free hepatic vein pressure (FHVP), predicts survival in patients with cirrhosis. It has been suggested for the use of inferior vena cava (IVC) value instead of FHVP to calculate HVPG when the difference between proximal FHVP (obtained at 2 cm from the hepatic vein outlet) and IVC (measured at the level of the hepatic ostium) is >2 mm Hg. However, there are no data supporting this recommendation. The main aim of the study was to establish which gradient, WHVP-FHVP (HVPG-Free) or WHVP-IVC (HVPG-IVC), better correlates with orthotopic liver transplantation (OLT)-free survival. This work was a retrospective evaluation of hepatic hemodynamic studies of 380 consecutive patients with cirrhosis performed from January 2006 to December 2012 with follow-up until December 2013. Patients had a mean age of 56±10 years and 64.7% were men. Mean Child-Pugh was 7±2. HVPG-Free (16±5 mm Hg) was significantly lower than HVPG-IVC (17±5.5 mm Hg; P<0.001). During a mean follow-up of 43 months, 40 patients were transplanted and 111 died. A total of 285 (75%) patients had an FHVP-IVC difference within ±2 mm Hg (no discrepancy) and 95 (25%) patients<-2 mm Hg or >2 mm Hg (discrepancy). In patients without discrepancy, 16 mm Hg was the best cut-off value predicting survival, independently of being calculated as HVPG-Free or HVPG-IVC. However, in those patients with discrepancy, 16 mm Hg was still the best cut-off value for HVPG-Free, but not for HVPG-IVC, among which 25 patients (26%) were misclassified regarding their risk of OLT/death.
CONCLUSIONS: Given that WHVP-FHVP was more accurate in assessing prognosis than WHVP-IVC, HVPG should be calculated as the gradient between WHVP and FHVP, but not with IVC, in order to optimize its prognostic value and in identifying different risk population.
© 2015 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2015        PMID: 26238376     DOI: 10.1002/hep.28031

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  17 in total

Review 1.  Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease.

Authors:  Gyorgy Baffy
Journal:  Dig Dis Sci       Date:  2018-01-22       Impact factor: 3.199

Review 2.  Portal pressure monitoring-state-of-the-art and future perspective.

Authors:  Gang Xu; Fei Li; Yilei Mao
Journal:  Ann Transl Med       Date:  2019-10

Review 3.  Proceedings from the 2018 Canadian Association for the Study of the Liver Single Topic Conference-Decompensated cirrhosis: from clinic to transplant.

Authors:  Victor Dong; Maxime Gosselin; Nishita Jagarlamudi; Beverley Kok; Mark G Swain; Jasmohan S Bajaj; Juan G Abraldes; Vladimir Marquez; R Todd Stravitz; Aldo J Montano-Loza; Manuela Merli; Phil Wong; Amanda Brisebois; Puneeta Tandon; Julia Wendon; Scott L Nyberg; François M Carrier; Michael R Lucey; Florence Wong; Jordan J Feld; Constantine J Karvellas; Christopher F Rose; Julien Bissonnette
Journal:  Can Liver J       Date:  2019-12-10

4.  Indocyanine Green Retention Rates at 15 min Predicted Hepatic Decompensation in a Western Population.

Authors:  Bertrand Le Roy; Emilie Grégoire; Cyril Cossé; Badr Serji; Nicolas Golse; René Adam; Daniel Cherqui; Jean-Yves Mabrut; Yves-Patrice Le Treut; Eric Vibert
Journal:  World J Surg       Date:  2018-08       Impact factor: 3.352

5.  The predictive value of baseline hepatic venous pressure gradient for variceal rebleeding in cirrhotic patients receiving secondary prevention.

Authors:  Chuan Liu; Yanna Liu; Ruoyang Shao; Sining Wang; Guangchuan Wang; Lifen Wang; Mingyan Zhang; Jinlin Hou; Chunqing Zhang; Xiaolong Qi
Journal:  Ann Transl Med       Date:  2020-02

6.  Non-invasive assessment of portal hypertension using quantitative magnetic resonance imaging.

Authors:  Naaventhan Palaniyappan; Eleanor Cox; Christopher Bradley; Robert Scott; Andrew Austin; Richard O'Neill; Greg Ramjas; Simon Travis; Hilary White; Rajeev Singh; Peter Thurley; Indra Neil Guha; Susan Francis; Guruprasad Padur Aithal
Journal:  J Hepatol       Date:  2016-07-27       Impact factor: 25.083

7.  CT perfusion imaging of the liver and the spleen in patients with cirrhosis: Is there a correlation between perfusion and portal venous hypertension?

Authors:  Emina Talakić; Silvia Schaffellner; Daniela Kniepeiss; Helmut Mueller; Rudolf Stauber; Franz Quehenberger; Helmut Schoellnast
Journal:  Eur Radiol       Date:  2017-03-20       Impact factor: 5.315

Review 8.  Diagnosis of cirrhosis and portal hypertension: imaging, non-invasive markers of fibrosis and liver biopsy.

Authors:  Bogdan Procopet; Annalisa Berzigotti
Journal:  Gastroenterol Rep (Oxf)       Date:  2017-04-17

9.  Portal hypertension is the main driver of liver stiffness in advanced liver cirrhosis.

Authors:  M Lunova; S Frankova; H Gottfriedova; R Senkerikova; M Neroldova; J Kovac; E Kieslichova; V Lanska; E Sticova; J Spicak; M Jirsa; J Sperl
Journal:  Physiol Res       Date:  2021-06-01       Impact factor: 1.881

10.  Non-invasive predictive model for hepatic venous pressure gradient based on a 3-dimensional computed tomography volume rendering technology.

Authors:  Yujen Tseng; Lili Ma; Tiancheng Luo; Xiaoqing Zeng; Na Li; Yichao Wei; Ji Zhou; Feng Li; Shiyao Chen
Journal:  Exp Ther Med       Date:  2018-01-30       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.